Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Gitte‐Bettina Nyvang"'
Autor:
Sara Bønløkke, Torben Steiniche, Boe Sandahl Sorensen, Gitte‐Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakær, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Magnus Stougaard
Publikováno v:
Molecular Oncology, Vol 18, Iss 5, Pp 1231-1244 (2024)
For cervical cancer (CC), circulating cell‐free HPV DNA (ccfHPV) may establish disease severity. Furthermore, HPV integration has been correlated to viral load and survival. In this study, pre‐treatment plasma from 139 CC cases (50 primary surger
Externí odkaz:
https://doaj.org/article/ff0349f899b14681a67f3aa4b23c11ad
Autor:
Sara Bønløkke, Magnus Stougaard, Boe Sandahl Sorensen, Berit Bargum Booth, Estrid Høgdall, Gitte-Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakær, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Torben Steiniche
Publikováno v:
Cells, Vol 11, Iss 14, p 2170 (2022)
Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. Blood
Externí odkaz:
https://doaj.org/article/06bef8557aa5496f8f8b269ac5a6d902
Autor:
Maximilian Konrad, Irene Hazell, Anja Ør Knudsen, Gitte-Bettina Nyvang, Carsten Brink, Michael Andersen Lomholt, Ebbe Laugaard Lorenzen
Introduction In MR-guided brachytherapy, organs at risk (OAR) are manually segmented during the planning process while the patient waits for the treatment to start with the applicator already in place. In this study we trained a nnU-Net to support on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2efd0ddb1d9534c394fce386ce05a4b3
Autor:
Aikou Okamoto, Jae-Weon Kim, Rutie Yin, Fabian Trillsch, Alexander Reuss, Carol Aghajanian, Maria Jesús Rubio-Pérez, Mehmet Ali Vardar, Giovanni Scambia, Anne Floquet, Gitte-Bettina Nyvang, Nicoletta Colombo, Mariusz Bidzinski, Christian Marth, Stéphanie Lheureux, Els Van Nieuwenhuysen, Paul Rugman, Jonathan Wessen, Philipp Harter
Publikováno v:
Gynecologic Oncology. 166:S170
Autor:
P. Krause, M. øller, Tine Schytte, A.S.B. Smedegaard Bertelsen, Gitte-Bettina Nyvang, A. Ør Knudsen, Uffe Bernchou
Publikováno v:
Radiotherapy and Oncology. 161:S1058
Autor:
Bente Lund, Line Bjørge, Anders Krog Vistisen, Gitte Bettina Nyvang, Sakari Hietanen, Gabriel Lindahl, Avanova investigators, Michael J. Birrer, Elisabeth Åvall Lundqvist, Susanne Malander, Mansoor Raza Mirza, Johanna Mäenpää, Henrik Roed, Ulla Peen, Theresa L. Werner, Synnöve Staff, Maria Dimoula, René dePont Christensen, Anja Ør Knudsen, Maarit Anttila
Publikováno v:
Mirza, M R, Åvall Lundqvist, E, Birrer, M J, dePont Christensen, R, Nyvang, G-B, Malander, S, Anttila, M, Werner, T L, Lund, B, Lindahl, G, Hietanen, S, Peen, U, Dimoula, M, Roed, H, Ør Knudsen, A, Staff, S, Krog Vistisen, A, Bjørge, L, Mäenpää, J U, AVANOVA investigators & Lund, B 2019, ' Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24) : a randomised, phase 2, superiority trial ', The Lancet. Oncology, vol. 20, no. 10, pp. 1409-1419 . https://doi.org/10.1016/S1470-2045(19)30515-7
Mirza, M R, Åvall Lundqvist, E, Birrer, M J, dePont Christensen, R, Nyvang, G B, Malander, S, Anttila, M, Werner, T L, Lund, B, Lindahl, G, Hietanen, S, Peen, U, Dimoula, M, Roed, H, Ør Knudsen, A, Staff, S, Krog Vistisen, A, Bjørge, L, Mäenpää, J U & AVANOVA investigators 2019, ' Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24) : a randomised, phase 2, superiority trial ', The Lancet Oncology, vol. 20, no. 10, pp. 1409-1419 . https://doi.org/10.1016/S1470-2045(19)30515-7
Mirza, M R, Åvall Lundqvist, E, Birrer, M J, dePont Christensen, R, Nyvang, G B, Malander, S, Anttila, M, Werner, T L, Lund, B, Lindahl, G, Hietanen, S, Peen, U, Dimoula, M, Roed, H, Ør Knudsen, A, Staff, S, Krog Vistisen, A, Bjørge, L, Mäenpää, J U & AVANOVA investigators 2019, ' Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24) : a randomised, phase 2, superiority trial ', The Lancet Oncology, vol. 20, no. 10, pp. 1409-1419 . https://doi.org/10.1016/S1470-2045(19)30515-7
BACKGROUND: Platinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both significantly improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b0d489f4cf81bc9d1fb6397f7039e5
https://vbn.aau.dk/da/publications/91c5e494-1b89-40ad-8438-89f8a9f88c45
https://vbn.aau.dk/da/publications/91c5e494-1b89-40ad-8438-89f8a9f88c45
Publikováno v:
Ør Knudsen, A, Schledermann, D, Nyvang, G-B, Mogensen, O, Herrstedt, J & Academy of Geriatric Cancer Research (AgeCare) 2016, ' Trends in gynecologic cancer among elderly women in Denmark, 1980-2012 ', Acta Oncologica, vol. 55, no. Suppl. 1, pp. 65-73 . https://doi.org/10.3109/0284186X.2015.1115119
Background The aim of this analysis was to describe trends in incidence, mortality, prevalence, and survival in Danish women with gynecologic cancer from 1980-2012 comparing women aged 70 years or more with younger women. Material and methods Gynecol
Autor:
Fabian Trillsch, Carol Aghajanian, Philip Twumasi-Ankrah, Paul Rugman, Mariusz Bidziński, Aikou Okamoto, Nicoletta Colombo, Els Van Nieuwenhuysen, Jasmine Lichfield, Philipp Harter, Stephanie Lheureux, Giovanni Scambia, Maria Jesus Rubio Pérez, Alexander Reuss, Gitte-Bettina Nyvang, Mehmet Ali Vardar, Jae Weon Kim, Christian Marth, Anne Floquet
Publikováno v:
Journal of Clinical Oncology. 37:TPS5598-TPS5598
TPS5598 Background: Ovarian cancer (OC) is the leading cause of death from gynecologic cancers in US women. Despite high response rates to first-line treatment, ~70% of patients (pts) relapse within 3 years and then remain largely incurable. First-li
Autor:
Jacob Christian Lindegaard, Kari Tanderup, Erik Morre Pedersen, Søren Kynde Nielsen, Gitte-Bettina Nyvang, Lisbeth Røhl, Lars Fokdal, T. Aagaard
Publikováno v:
Tanderup, K, Nielsen, S K, Nyvang, G-B, Pedersen, E M, Røhl, L, Aagaard, T, Fokdal, L & Lindegaard, J C 2010, ' From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer ', Radiotherapy & Oncology, vol. 94, no. 2, pp. 173-80 . https://doi.org/10.1016/j.radonc.2010.01.001
Udgivelsesdato: 2010-Feb BACKGROUND AND PURPOSE: Brachytherapy in locally advanced cervical cancer is still widely based on 2D standard dose planning, although 3D image guidance is available. The purpose of this study was to compare point doses to 3D
Autor:
Sara Bønløkke, Jan Blaakær, Boe Sandahl Sørensen, Gitte-Bettina Nyvang, Jacob Christian Lindegaard, Katrine Fuglsang, Magnus Stougaard, Torben Steiniche
Publikováno v:
Aarhus University
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::45b1ceee3da5fe5cabaec8cabae82332
https://pure.au.dk/portal/en/publications/hpv-dna-in-the-blood-of-cervical-cancer-patients--clinical-implications(514e82e7-c75a-4feb-8c1a-a1ef378e9b65).html
https://pure.au.dk/portal/en/publications/hpv-dna-in-the-blood-of-cervical-cancer-patients--clinical-implications(514e82e7-c75a-4feb-8c1a-a1ef378e9b65).html